Novel Platform Technologies for Accelerating the Development and Clinical Production of self-amplifying RNA Vaccines
Monday, July 26th - 9am EDT
|
Sponsored By:
|
|
The COVID-19 pandemic has unveiled the therapeutic potential of messenger RNA (mRNA) vaccines. mRNA vaccines utilize a synthetic nucleic acid equipping cells to express a target antigen which induces an immune response and protection against the virus. Self-amplifying mRNA (saRNA) builds on this cellular mechanism by replicating within a cell, thus requiring lower doses and enabling higher efficacy. For stability and intracellular delivery, the mRNA or saRNA is encapsulated within lipid nanoparticles (LNPs). The synthetic production methods for both mRNA and LNPs enable rapid and cost-effective development of these RNA vaccines starting from a gene sequence.
Precision Nanosystems Inc. offers a complete toolkit for creating saRNA vaccines, including a novel saRNA platform, GenVoy™ lipid delivery reagents and proprietary NxGen™ microfluidic manufacturing instrumentation. In this talk, we will review the key technology pillars needed for RNA vaccines and present recent scientific data from the development of saRNA vaccines against COVID-19 and Influenza that demonstrate PNI’s complete solution for rapid preclinical and clinical development of RNA vaccines.
Precision Nanosystems Inc. offers a complete toolkit for creating saRNA vaccines, including a novel saRNA platform, GenVoy™ lipid delivery reagents and proprietary NxGen™ microfluidic manufacturing instrumentation. In this talk, we will review the key technology pillars needed for RNA vaccines and present recent scientific data from the development of saRNA vaccines against COVID-19 and Influenza that demonstrate PNI’s complete solution for rapid preclinical and clinical development of RNA vaccines.
